Cresilon

The company provides contact channels at 86 34th Street, Suite D603/D604, Brooklyn, NY 11232, by phone at +1 (347) 435-2226, and by email for investment, sales, media, other inquiries, complaints, and feedback.

The company’s plant-based technology stops traumatic and surgical bleeding in seconds without manual pressure.

Cresilon provides a solution to stop bleeding.

Cresilon Inc. introduces a compact, one-handed version of its TRAUMAGEL hemostatic gel for first responders. The updated design maintains the original gel technology while reducing size for easier deployment in emergency settings. The product will debut at EMS World 2026.

Sep 2026CresilonNews article

Cresilon secures an Innovative Technology contract from Vizient for its hemostatic gel **TRAUMAGEL**, following evaluation by hospital experts. Vizient, the largest provider-driven healthcare performance improvement company, awards the contract to advance medical products improving trauma care. TRAUMAGEL targets bleeding control in healthcare settings, aligning with Vizient’s focus on performance-driven solutions.

Mar 2026CresilonNews article

Cresilon partners with McCarthy Vet to distribute **VETIGEL**, a plant-based hemostatic gel designed to stop and control bleeding in veterinary surgeries. The agreement expands access for veterinarian surgeons across Canada. VETIGEL offers an instant, plant-derived alternative for surgical bleeding management.

Jun 2025CresilonNews article

Cresilon launches **TRAUMAGEL**, the first syringe-delivered hydrogel for treating traumatic hemorrhage. The product is the only flowable hemostatic cleared for temporary external use to control moderate to severe bleeding. It leverages Cresilon’s proprietary hydrogel technology to address critical bleeding scenarios.

Jan 2025CresilonNews article